Singapore markets closed

Stoke Therapeutics, Inc. (STOK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.86-1.31 (-9.21%)
As of 01:06PM EDT. Market open.

Stoke Therapeutics, Inc.

45 Wiggins Avenue
Bedford, MA 01730
United States
781 430 8200
https://www.stoketherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees110

Key executives

NameTitlePayExercisedYear born
Dr. Edward M. Kaye M.D., Ph.D.CEO & Director931.21kN/A1949
Dr. Adrian R. Krainer Ph.D.Co-Founder & Independent Director44kN/A1959
Mr. Stephen J. Tulipano CPA, MBAChief Financial Officer619.09kN/A1959
Dr. Barry S. Ticho FACC, M.D., Ph.D.Chief Medical Officer688.83kN/A1961
Ms. Isabel Aznarez Ph.D.Co-Founder & Group VP of Discovery ResearchN/AN/A1973
Dr. Huw M. Nash Ph.D.COO & Chief Business Officer429.67kN/A1967
Mr. Eric RojasHead of Investor RelationsN/AN/AN/A
Mr. Jonathan Allan J.D.Corporate Secretary & General CounselN/AN/A1990
Ms. Dawn KalmarChief Communications OfficerN/AN/A1978
Ms. Joan WoodChief Human Resources OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Corporate governance

Stoke Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.